<DOC>
	<DOCNO>NCT02230904</DOCNO>
	<brief_summary>The primary objective study compare adhesiveness 2 different patch formulation Rotigotine use large patch size 40 cm^2 , assumption patch formulation show similar adhesiveness property .</brief_summary>
	<brief_title>A Study Compare Adhesiveness 2 Different Rotigotine Patches Used Treatment Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject diagnosis idiopathic Parkinson 's Disease Subject continuous treatment commercially available Rotigotine transdermal patch ( NeuproÂ® ) least 3 month prior enrollment Subject take stable Rotigotine dose include 8 mg/24 hour ( 40 cm^2 ) patch least 2 week prior enrollment Subject medical psychiatric condition , opinion investigator , could jeopardize would compromise subject 's wellbeing ability participate study Subject history significant skin hypersensitivity adhesives transdermal product recently unsolved contact dermatitis Subject history present condition atopic eczematous Dermatitis , Psoriasis , active skin disease Subject lifetime history suicide attempt ( include active attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( 'yes ' ) either Question 4 Question 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Screening ( Visit 1 ) Baseline ( Visit 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Rotigotine patch</keyword>
	<keyword>Neupro</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>